- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01292525
Protocol Calcineurin Inhibitor (CNI) Weaning
22 mars 2016 uppdaterad av: Nantes University Hospital
Prospective, Multicenter, Randomized, Double-blind, Controlled Parallel Group Study Designed to Assess the Risk-benefit Balance of the Gradual Withdrawal of a Calcineurin Inhibitor (Tacrolimus) in Renal Transplant Patients Over 4 Years and Clinically Selected
The main objective of this study is to demonstrate the benefit of the withdrawal of Tacrolimus (Prograf®) on renal function in patients one year after the end of the weaning period.
The secondary objectives will focus on assessing the risks and consequences of withdrawal of Tacrolimus (Prograf®).
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
16
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Nantes, Frankrike, 44093
- Nantes University Hospital
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 80 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Pre-inclusion criteria :
- Male or female aged between 18 and 80 years (inclusive),
- Having received a deceased donor transplant or living with ABO compatibility,
- First renal allograft for at least 4 years and under 10 years,
- Presenting a stable renal function : serum creatinine with a variation of ± 25% of the average of the year before inclusion,
- Treated with tacrolimus (Prograf®) in combination with MPA (Cellcept® and Myfortic®) + / - steroids (between 5 and 10 mg per day),
- Patient has given informed consent,
- Patient insured,
- Patient (of childbearing age) with effective contraception.
Inclusion Criteria:
- Glomerular Filtration Rate (GFR), defined by the dosage of cystatin C ≥ 40 ml/min/1, 73m²,
- Proteinuria ≤ 0,5 g / day,
- Patient with serum levels of Tacrolimus between 5 to 10 ng / ml on average during the last 6 months (inclusive). It is accepted that 25% of the assays performed during the last 6 months, serum levels of tacrolimus are outside the limits mentioned above (5-10 ng / ml). They must nevertheless be between 3.5 to 12.5 ng / ml (inclusive).
- Patient with serum levels of MPA (Cellcept® and Myfortic®) higher ≥ 30 mg / ml,
- No anti-HLA antibodies at the time of inclusion, verified using highly sensitive techniques (Luminex HD),
- Lack of histological evidence of cellular or humoral acute or chronic or subclinical rejection on renal graft according to the latest classification of Banff 2009.
Exclusion Criteria:
- Patients under age 18 or over 80 years,
- Transplanted from less than 4 years and over 10 years,
- Patients re-transplanted,
- Transplantation of several organs,
- Patient not treated with tacrolimus as maintenance therapy,
- Serum levels of Tacrolimus patient <5 or >10 ng / ml,
- Serum levels of MPA of the patient <30 mg / ml,
- Patients treated with other immunosuppressive drugs that Tacrolimus (Prograf®), MPA (Cellcept® and Myfortic®) and steroids,
- Patient not having a stable graft function at baseline (change in serum creatinine > 25% of the average of the year before inclusion in the study), with a GFR defined by the dosage of cystatin C <40 ml/min/1, 73m² at the time of inclusion,- Patients with proteinuria > 0.5 g at study entry,
- Patient with HLA antibodies at study entry,
- Patient non-compliant,
- Presence of histological evidence of cellular or humoral acute or chronic or subclinical rejection on renal graft according to the latest classification of Banff 2009,
- History of lymphoproliferative disorders,
- Diagnosis of a malignancy within 5 years before enrollment,
- Significantly abnormal hematologic data of a clinical standpoint, as determined by the investigator for hematocrit, hemoglobin, white blood cell count or platelets,
- Data significantly abnormal blood biochemistry of a clinical standpoint, as determined by the investigator,
- Abuse of significant drug or alcohol at the time of inclusion, determined by the investigator,
- Patient positive for antibodies to hepatitis C or hepatitis B surface antigen of hepatitis B (HBsAg) or HIV infection,
- Participation in a clinical study within 3 months,
- Pregnancy, Breastfeeding.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Tacrolimus
|
A control group continued conventional therapy, Tacrolimus (Prograf®) ("control" group) and will be followed in parallel group "withdrawal" that will stop treatment with Tacrolimus (Prograf®).
|
Experimentell: Withdrawal of Tacrolimus
|
Patients randomized to the "withdrawal"group will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose).
The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60).
The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120).
The withdrawal of Tacrolimus (Prograf®) will be obtained in four months.
Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the "withdrawal" group.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Renal function
Tidsram: one year after complete withdrawal of Tacrolimus
|
The primary endpoint will be the improvement of renal function one year after complete withdrawal of Tacrolimus (Prograf®) assessed by measuring the glomerular filtration rate (GFR) calculated by the dosage of cystatin C according to the equation Bricon.
The DFG will be compared between times J-30 and J480 (1 year after the withdrawal).
|
one year after complete withdrawal of Tacrolimus
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Renal function
Tidsram: one year after complete withdrawal
|
Improvement of renal function by measuring serum creatinine, using the original MDRD equation,
|
one year after complete withdrawal
|
Acute rejection
Tidsram: one year after complete withdrawal
|
Rate of histologically proven acute rejection by biopsy according to Banff classification 2009,
|
one year after complete withdrawal
|
Chronic rejection
Tidsram: One year after complete withdrawal
|
Rate of chronic rejection histologically proven by biopsy according to Banff classification 2009,
|
One year after complete withdrawal
|
Steroid-resistant rejection
Tidsram: One year after complete withdrawal
|
Rates of steroid-resistant rejection
|
One year after complete withdrawal
|
Graft survival
Tidsram: One year after complete withdrawal
|
Rate of return to dialysis (graft survival)
|
One year after complete withdrawal
|
Cancer and infections
Tidsram: one year after complete withdrawal
|
Incidence of cancer and infections
|
one year after complete withdrawal
|
Patients survival
Tidsram: One year after complete withdrawal
|
Survival rate of patients
|
One year after complete withdrawal
|
Anti-HLA antibodies
Tidsram: One year after complete withdrawal
|
Appearance of anti-HLA donor specific and non-donor specific antibodies measured by the technique Luminex
|
One year after complete withdrawal
|
Histological lesions of rejection
Tidsram: One year after complete withdrawal
|
The appearance of histological lesions of cellular or humoral acute or chronic or subclinical rejection on the biopsy protocol
|
One year after complete withdrawal
|
Histological lesions of fibrosis
Tidsram: One year after complete withdrawal
|
Onset or worsening of histological lesions of interstitial fibrosis and tubular atrophy on biopsy inflammatory
|
One year after complete withdrawal
|
Hypertension, hyperglycemia and hyperlipidemia
Tidsram: One year after complete withdrawal
|
Incidence of hypertension, hyperglycemia and hyperlipidemia
|
One year after complete withdrawal
|
Quality of life
Tidsram: One year after complete withdrawal
|
Determination of the benefits of withdrawal of Tacrolimus on the quality of life of patients, defined by the scale of quality of life validated SF-36 used at the beginning (J-15) and at the end of the weaning period (J120) at 6 months (J300) and one year after complete withdrawal of Tacrolimus (J480)
|
One year after complete withdrawal
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studiestol: Emmanuel MORELON, Profesor, Chu de Lyon
- Huvudutredare: Magali GIRAL, Profesor, CHU de Nantes
- Studiestol: Jean-Paul SOULILLOU, Profesor, CHU de Nantes
- Studiestol: Christophe LEGENDRE, Profesor, Hôpital Necker - AP-HP
- Studiestol: Georges MOURAD, Profesor, CHU de Montpellier
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 maj 2011
Primärt slutförande (Faktisk)
1 maj 2015
Avslutad studie (Faktisk)
1 maj 2015
Studieregistreringsdatum
Först inskickad
8 februari 2011
Först inskickad som uppfyllde QC-kriterierna
8 februari 2011
Första postat (Uppskatta)
9 februari 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
23 mars 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 mars 2016
Senast verifierad
1 maj 2015
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 09/7-D
- 2010-019574-33 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Funktion av njurtransplantation
-
Incyte CorporationTillgängligtSTAT1 Gain-of-Function Disease
-
Abramson Cancer Center of the University of PennsylvaniaIndragenCancerpatienter som genomgår stamcellstransplantation (RCT of ACP for Transplant)
-
Boston Medical CenterThe New School for Social Research; Children's Bureau - Administration...IndragenFöräldrastress | Föräldraskap | Familjerelationer | Familjekonflikt | Mor-barn relationer | Förälders barnmisshandel | Childhood Disorder of Social Function, OspecificeradFörenta staterna
-
Hans BahlmannLinkoeping UniversityRekryteringNjurcancer | Uretercancer | Andra specificerade störningar av njure och urinledare | Benign Neoplasm av Ureter | Calculus of Kidney and Ureter | Ureterisk reflux | Medfödd ureteranomali | Benign renal neoplasmSverige
-
UK Kidney AssociationRekryteringVaskulit | AL Amyloidos | Tuberös skleros | Fabrys sjukdom | Cystinuri | Fokal segmentell glomeruloskleros | IgA nefropati | Bartters syndrom | Pure Red Cell Aplasia | Membranös nefropati | Atypiskt hemolytiskt uremiskt syndrom | Autosomal dominant polycystisk njursjukdom | Cystinos | Nefronoftis | BK nefropati | Kalcifylax | Gitelmans syndrom och andra villkorStorbritannien
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins... och andra samarbetspartnersRekryteringMitokondriella sjukdomar | Retinit Pigmentosa | Myasthenia Gravis | Eosinofil gastroenterit | Multipel systematrofi | Leiomyosarkom | Leukodystrofi | Anal fistel | Spinocerebellär ataxi typ 3 | Friedreich Ataxi | Kennedys sjukdom | Borreliainfektion | Hemofagocytisk lymfohistiocytos | Spinocerebellär ataxi typ 1 | Spinocerebellär... och andra villkorFörenta staterna, Australien
Kliniska prövningar på Tacrolimus
-
Hospital Universitari de BellvitgeAvslutad
-
Astellas Pharma IncAvslutad
-
Nantes University HospitalHar inte rekryterat ännuOrgantransplantatNorge, Spanien, Frankrike
-
Hospices Civils de LyonAvslutadHemorragisk ärftlig telangiektasi (HHT)Frankrike
-
Poitiers University HospitalChiesi Farmaceutici S.p.A.AvslutadImmunsuppression | NjurtransplantationFrankrike
-
Taro Pharmaceuticals USAAvslutad
-
Vanderbilt University Medical CenterVeloxis PharmaceuticalsRekryteringNjurtransplantationFörenta staterna
-
Hospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... och andra samarbetspartnersAvslutadMEMBRANÖS NEFROPATISpanien
-
AZ-VUBFund for Scientific Research, Flanders, Belgium; Belgian GovernmentAvslutadTyp 1-diabetes | ÖtransplantationBelgien
-
University of MinnesotaIndragenNjurtransplantat dysfunktionFörenta staterna